U.S. License Holder:
Eli Lilly & Co.
Date of License:
September-13-2024
Last Update:
Oct-08-2024
FDA-Approved Indications
EBGLYSS (lebrikizumab-lbkz) is an interleukin-13 antagonist indicated for the treatment of adult and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.